کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
8769011 | 1597918 | 2018 | 33 صفحه PDF | دانلود رایگان |
عنوان انگلیسی مقاله ISI
New methodologies to accurately assess circulating active transforming growth factor-β1 levels: implications for evaluating heart failure and the impact of left ventricular assist devices
دانلود مقاله + سفارش ترجمه
دانلود مقاله ISI انگلیسی
رایگان برای ایرانیان
کلمات کلیدی
SMCATGF-β1TSP-1DCMvWFLVADChFPAI-1left ventricle - بطن چپcoronary artery disease - بیماری عروق کرونرtransforming growth factor beta 1 - تبدیل فاکتور رشد بتا 1Thrombospondin-1 - ترومبوسپوندن-1CAD - طراحی به کمک رایانه یا کَدVon Willebrand factor - عامل فون ویلبراندPlasminogen activator inhibitor-1 - مهار کننده فعال کننده پلاسمینوژن-1congestive heart failure - نارسایی احتقانی قلبheart failure - نارسایی قلبیDilated cardiomyopathy - کاردیومیوپاتی دیلاته، کاردیومیوپاتی کامل
موضوعات مرتبط
علوم پزشکی و سلامت
پزشکی و دندانپزشکی
پزشکی و دندانپزشکی (عمومی)
پیش نمایش صفحه اول مقاله
چکیده انگلیسی
Transforming growth factor-β1 (TGF-β1) has been used as a biomarker in disorders associated with pathologic fibrosis. However, plasma TGF-β1 assessment is confounded by the significant variation in reported normal values, likely reflecting variable release of the large pool of platelet TGF-β1 after blood drawing. Moreover, current assays measure only total TGF-β1, which is dominated by the latent form of TGF-β1 rather than the biologically active form. To address these challenges, we developed methodologies to prevent ex vivo release of TGF-β1 and to quantify active TGF-β1. We then used these techniques to measure TGF-β1 in healthy controls and patients with heart failure (HF) before and after insertion of left ventricular assist devices (LVAD). Total plasma TGF-β1 was 1.0â±â0.60âng/mL in controls and 3.76â±â1.55âng/mL in subjects with HF (Pâ<â0.001), rising to 5.2â±â2.3âng/mL following LVAD placement (Pâ=â0.006). These results were paralleled by the active TGF-β1 values; controls had 3-16âpg/mL active TGF-β1, whereas levels were 2.7-fold higher in patients with HF before, and 4.2-fold higher after, LVAD implantation. Total TGF-β1 correlated with levels of the platelet-derived protein thrombospondin-1 (râ=â0.87; Pâ<â0.001), suggesting that plasma TGF-β1 may serve as a surrogate indicator of in vivo platelet activation. von Willebrand factor high molecular weight multimers correlated inversely with TGF-β1 levels (râ=ââ0.63; Pâ=â0.023), suggesting a role for shear forces in loss of these multimers and platelet activation. In conclusion, accurate assessment of circulating TGF-β1 may provide a valuable biomarker for in vivo platelet activation and thrombotic disorders.
ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Translational Research - Volume 192, February 2018, Pages 15-29
Journal: Translational Research - Volume 192, February 2018, Pages 15-29
نویسندگان
Donna Mancini, Juan Monteagudo, Mayte Suárez-Fariñas, Jeffrey Bander, Rohan Varshney, Juana Gonzalez, Barry S. Coller, Jasimuddin Ahamed,